Intranasal Spravato (Esketamine)
Intranasal Spravato (Esketamine) is sometimes used as part of a multidisciplinary therapy program to help patients coping with Treatment-Resistant Depression. Our expert medical clinicians are available to guide patients dealing with Treatment-Resistant Depression about the use of Spravato (Esketamine) and other treatment options.
What Is Spravato (Esketamine)?
Spravato (Esketamine) is a prescription medication used for Treatment-Resistant Depression in adults. It is used as a nasal spray and is taken alongside an oral antidepressant medication.
Spravato (Esketamine) treatment is offered via the Spravato (Esketamine) REMS (Risk Evaluation and Mitigation Strategy) Program. This program ensures Spravato (Esketamine) treatment is provided only to patients in a medically-supervised healthcare setting that is certified. It also verifies that each Spravato (Esketamine) patient receives full details about the adverse outcomes of sedation and the need for monitoring associated with treatment.
Spravato (Esketamine) treatment involves at least two hours of patient observation by a healthcare provider, and Spravato (Esketamine) nasal spray cannot be given to a patient for home use. Our medical clinicians offer Spravato (Esketamine) nasal spray treatment for Treatment-Resistant Depression as a form of ketamine therapy.
What Is Spravato (Esketamine) Nasal Spray?
Ketamine is a short-term treatment for Treatment-Resistant Unipolar and Bipolar Major Depressive Disorder (MDD). After an intravenous ketamine treatment, a patient may experience a short-term reduction in depression symptoms, Mayo Clinic reports.
Researchers are still unsure about how ketamine impacts the brain exactly, WebMD notes, and research is ongoing to determine if ketamine can provide a safe, effective treatment to help patients coping with Treatment-Resistant Unipolar and Bipolar MDD. Regardless, it is crucial for patients who are considering Spravato (Esketamine) nasal spray for Treatment-Resistant Depression to work with a healthcare provider. This ensures that these patients can safely explore Spravato (Esketamine) and other treatment options to help them effectively manage their depression symptoms.
Why Do You Need Esketamine from a Healthcare Provider?
For people who are coping with Treatment-Resistant Depression, esketamine treatment is available but it must be performed by an authorized healthcare provider. Esketamine abuse may cause physical side effects that disappear shortly after use, but the more frequently a person abuses the drug, the more likely it becomes that he or she will require more ketamine to achieve the same results as before. Thus, if a person becomes addicted to esketamine and abuses it regularly, a fatal overdose may occur.
Esketamine treatments must be administered only by an authorized healthcare provider, otherwise there could be a serious risk of ketamine abuse, WebMD states. Therefore, it is important to consult with a medical clinician before using Spravato esketamine nasal spray or any other form of esketamine treatment.
Our medical clinicians explain all aspects of a Spravato treatment before it is performed. They help a patient determine if he or she is a good candidate for Spravato (Esketamine) ketamine therapy, and only recommend this form of depression therapy if they believe it will be safe and effective.
Additionally, our medical clinicians provide Spravato (Esketamine) ketamine therapy for Treatment-Resistant Depression, along with a broad range of comprehensive treatment options to help patients manage their depression symptoms. Our medical clinicians tailor each Treatment-Resistant Depression therapy program to a patient, thereby ensuring that he or she can address the biological, psychological, and social aspects of depression.
To learn more about Spravato (Esketamine) therapy and other Treatment-Resistant Depression therapies, please contact us online or call us today at (858) 427-5060.